Pharmacological treatments

[en] This chapter reviews the current state of knowledge about pharmacological treatments acting on the recovery of consciousness in patients with severe brain injury. Potential pharmacological agents (amantadine, apomorphine, levodopa, methylphenidate, bromocriptine, modafinil, selegiline, zolpidem, and baclofen) and their underlying mechanisms are examined. Clinical considerations, off-label use of specific medication, limitations of current research, and future directions are also outlined. Finally, we discuss the potential of whole-brain computational modelling to test treatments in-silico whilst also driving forward the understanding of the mechanisms of consciousness.

Disciplines :

Neurology

Author, co-author :

Szymkowicz, Emilie ^✱; Université de Liège - ULiège > GIGA ; CHU Liège - Central University Hospital of Liege [BE] > Centre du Cerveau2

Alnagger, Naji ^✱; Université de Liège - ULiège > GIGA > GIGA Consciousness - Coma Science Group ; CHU Liège - Central University Hospital of Liege [BE] > Centre du Cerveau2

Seyfzadehdarabad, Fatemeh ; Université de Liège - ULiège > GIGA ; CHU Liège - Central University Hospital of Liege [BE] > Centre du Cerveau2

Cardone, Paolo ; Université de Liège - ULiège > GIGA > GIGA Consciousness - Coma Science Group ; CHU Liège - Central University Hospital of Liege [BE] > Centre du Cerveau2

Whyte, John; Moss Rehabilitation Research Institute and MossRehab,

Gosseries, Olivia ; Université de Liège - ULiège > GIGA > GIGA Consciousness - Coma Science Group ; CHU Liège - Central University Hospital of Liege [BE] > Centre du Cerveau2

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Pharmacological treatments

Publication date :

2023

Main work title :

Coma and Disorders of Consciousness

Author, co-author :

Laureys, Steven ; Centre Hospitalier Universitaire de Liège - CHU > > Centre du Cerveau² ; Université de Liège - ULiège > GIGA > GIGA Consciousness

Editor :

Schnakers, Caroline

Publisher :

Springer, New York, United States

Edition :

3rd

Peer reviewed :

Editorial reviewed

Available on ORBi :

since 19 July 2023

Statistics

Number of views

97 (35 by ULiège)

Number of downloads

9 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Plum F, Posner JB. The diagnosis of stupor and coma. Contemp Neurol Ser. 1972;10:1–286.
Laureys S, Celesia GG, Cohadon F, Lavrijsen J, León-Carrión J, Sannita WG, et al. Unresponsive wakefulness syndrome: a new name for the vegetative state or apallic syndrome. BMC Med. 2010;8(1):68.
Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state. N Engl J Med. 1994;330(21):1499–508.
Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz DI, et al. The minimally conscious state: definition and diagnostic criteria. Neurology. 2002;58(3):349–53.
Klingshirn H, Grill E, Bender A, Strobl R, Mittrach R, Braitmayer K, et al. Quality of evidence of rehabilitation interventions in long-term care for people with severe disorders of consciousness after brain injury: a systematic review. J Rehabil Med. 2015;47(7):577–85.
Giacino J, Katz D, Whyte J. Neurorehabilitation in disorders of consciousness. Semin Neurol. 2013;33(02):142–56.
Seel RT, Douglas J, Dennison AC, Heaner S, Farris K, Rogers C. Specialized early treatment for persons with disorders of consciousness: program components and outcomes. Arch Phys Med Rehabil. 2013;94(10):1908–23.
Thibaut A, Schiff N, Giacino J, Laureys S, Gosseries O. Therapeutic interventions in patients with prolonged disorders of consciousness. Lancet Neurol. 2019;18(6):600–14.
Edlow BL, Sanz LRD, Polizzotto L, Pouratian N, Rolston JD, Snider SB, et al. Therapies to restore consciousness in patients with severe brain injuries: a gap analysis and future directions. Neurocrit Care. 2021;35(S1):68–85.
Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. 2014;20(26):4167–84.
Ciurleo R, Bramanti P, Calabrò RS. Pharmacotherapy for disorders of consciousness: are ‘awakening’ drugs really a possibility? Drugs. 2013;73(17):1849–62.
Khan SM, Carter GT, Aggarwal SK, Holland J. Psychedelics for brain injury: a mini-review. Front Neurol. 2021;12:685085.
Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366(9):819–26.
Alavijeh MS, Palmer AM. Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds. Neurobiol Dis. 2010;37(1):38–47.
Luppi AI, Cain J, Spindler LRB, Górska UJ, Toker D, Hudson AE, et al. Mechanisms underlying disorders of consciousness: bridging gaps to move toward an integrated translational science. Neurocrit Care. 2021;35(S1):37–54.
Ma HM, Zafonte RD. Amantadine and memantine: a comprehensive review for acquired brain injury. Brain Inj. 2020;34(3):299–315.
Barra ME, Edlow BL, Brophy GM. Pharmacologic therapies to promote recovery of consciousness. Semin Neurol. 2022;42(03):335–47.
Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. Practice guideline update recommendations summary: disorders of consciousness: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. 2018;91(10):450–60.
Rühl L, Kuramatsu JB, Sembill JA, Kallmünzer B, Madzar D, Gerner ST, et al. Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury. J Neurol Neurosurg Psychiatry. 2022;93(6):582–7.
Ghalaenovi H, Fattahi A, Koohpayehzadeh J, Khodadost M, Fatahi N, Taheri M, et al. The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Inj. 2018;32(8):1050–5.
Shimia M, Iranmehr A, Valizadeh A, Mirzaei F, Namvar M, Rafiei E, et al. A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury. J Neurosurg Sci. 2023;67(5):598–604.
Akcil EF, Korkmaz Dilmen O, Vehid H, Tunali Y. Can amantadine ameliorate neurocognitive functions after subarachnoid haemorrhage? A preliminary study. Turk J Anaesth Reanim. 2018;46:100–7.
Patrick PD, Blackman JA, Mabry JL, Buck ML, Gurka MJ, Conaway MR. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol. 2006;21(10):879–85.
McMahon MA, Vargus-Adams JN, Michaud LJ, Bean J. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil. 2009;88(7):525–32.
Abbasivash R, Valizade Hasanloei MA, Kazempour A, Mahdkhah A, Shaaf Ghoreishi MM, Akhavan Masoumi G. The effect of oral administration of amantadine on neurological outcome of patients with diffuse axonal injury in ICU. J Exp Neurosci. 2019;13:117906951882485.
Hadgu RM, Borghol A, Gillard C, Wilson C, Elqess Mossa S, McKay M, et al. Evaluation of outcomes in patients receiving amantadine to improve alertness after traumatic brain injury. Hosp Pharm. 2021;56(5):486–94.
Gao Y, Zhang Y, Li Z, Ma L, Yang J. Persistent vegetative state after severe cerebral hemorrhage treated with amantadine: a retrospective controlled study. Medicine. 2020;99(33):e21822.
Whyte J, Gosseries O, Chervoneva I, DiPasquale MC, Giacino J, Kalmar K, et al. Predictors of short-term outcome in brain-injured patients with disorders of consciousness. In: Progress in brain research [Internet]. Elsevier; 2009. p. 63–72. https://linkinghub.elsevier.com/retrieve/pii/S0079612309177063.
Alkhachroum A, Eliseyev A, Der-Nigoghossian CA, Rubinos C, Kromm JA, Mathews E, et al. EEG to detect early recovery of consciousness in amantadine-treated acute brain injury patients. J Neurol Neurosurg Psychiatry. 2020;91(6):675–6.
Shafiee S, Ehteshami S, Moosazadeh M, Aghapour S, Haddadi K. Placebo-controlled trial of oral amantadine and zolpidem efficacy on the outcome of patients with acute severe traumatic brain injury and diffuse axonal injury. Caspian J Intern Med. 2022;13(1).
Hintze TD, Small CE, Montgomery J, Reveles KR, Hafeez S, Barthol CA. Comparison of amantadine, modafinil, and standard of care in the acute treatment of disorders of consciousness after severe traumatic brain injury. Clin Neuropharmacol. 2022;45(1):1–6.
Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, et al. Amantadine and modafinil as neurostimulants following acute stroke: a retrospective study of intensive care unit patients. Neurocrit Care. 2021;34(1):102–11.
Lee S, Lee H, Lee Y, Lee J. Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: a retrospective case-control study. J Rehabil Med. 2020;52(2):1–10.
Bender Pape TL, Herrold AA, Livengood SL, Guernon A, Weaver JA, Higgins JP, et al. A pilot trial examining the merits of combining amantadine and repetitive transcranial magnetic stimulation as an intervention for persons with disordered consciousness after TBI. J Head Trauma Rehabil. 2020;35(6):371–87.
Estraneo A, Pascarella A, Moretta P, Loreto V, Trojano L. Clinical and electroencephalographic on–off effect of amantadine in chronic non-traumatic minimally conscious state. J Neurol. 2015;262(6):1584–6.
FitzGerald A, Main L, Duff U, Foggo J, Rowney F, Haire N, et al. Does amantadine maintain function in long-established brain injury? A single case experimental design. Brain Inj. 2021;35(11):1443–50.
Chen X, Tang C, Zhou H, Li Z. Effect of amantadine on vegetative state after traumatic brain injury: a functional magnetic resonance imaging study. J Int Med Res. 2019;47(2):1015–24.
Zão A, Almeida AF, Beça G, Nunes R. From vegetative state to participation: amantadine as a trigger of the rehabilitation program. Acta Medica Port. 2020;33(9):604–9.
Lehnerer SM, Scheibe F, Buchert R, Kliesch S, Meisel A. Awakening with amantadine from a persistent vegetative state after subarachnoid haemorrhage. BMJ Case Rep. 2017;2017:bcr-2017-220305.
Horiguchi J, Inami Y, Shoda T. Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol. 1990;13(1):84–8.
Schnakers C, Hustinx R, Vandewalle G, Majerus S, Moonen G, Boly M, et al. Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry. 2008;79(2):225–7.
Zafonte RD, Watanabe T, Mann NR. Amantadine: a potential treatment for the minimally conscious state. Brain Inj. 1998;12(7):617–21.
Avecillas-Chasín JM, Barcia JA. Effect of amantadine in minimally conscious state of non-traumatic etiology. Acta Neurochir. 2014;156(7):1375–7.
Sanz LRD, Lejeune N, Blandiaux S, Bonin EAC, Raimondo F, Panda R, et al. Apomorphine treatment in a patient with chronic disorders of consciousness following brain hemorrhage. 13th World Congress on Brain Injury. 2019.
Chatelle C, Thibaut A, Gosseries O, Bruno MA, Demertzi A, Bernard C, et al. Changes in cerebral metabolism in patients with a minimally conscious state responding to zolpidem. Front Hum Neurosci. 2014;8:917. https://doi.org/10.3389/fnhum.2014.00917/abstract.
Williams ST, Conte MM, Goldfine AM, Noirhomme Q, Gosseries O, Thonnard M, et al. Common resting brain dynamics indicate a possible mechanism underlying zolpidem response in severe brain injury. eLife. 2013;2:e01157.
Sripad P, Rosenberg J, Boers F, Filss CP, Galldiks N, Langen KJ, et al. Effect of zolpidem in the aftermath of traumatic brain injury: an MEG study. Case Rep Neurol Med. 2020;2020:1–8.
Ribaric S. The pharmacological properties and therapeutic use of apomorphine. Molecules. 2012;17(5):5289–309.
Fridman EA, Calvar J, Bonetto M, Gamzu E, Krimchansky BZ, Meli F, et al. Fast awakening from minimally conscious state with apomorphine. Brain Inj. 2009;23(2):172–7.
Fridman EA, Krimchansky BZ, Bonetto M, Galperin T, Gamzu ER, Leiguarda RC, et al. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. 2010;24(4):636–41.
Sanz LRD, Szymkowicz E, Lejeune N, Bonin EAC, Sala A, Panda R, et al. Multimodal open-label study of apomorphine in disorders of consciousness. Abstract presented at: 14th Biennial World Congress on Brain Injury; 2023. Dublin, Ireland. Available from: https://hdl.handle.net/2268/301689.
Sanz LRD, Lejeune N, Blandiaux S, Bonin E, Thibaut A, Stender J, et al. Treating disorders of consciousness with apomorphine: protocol for a double-blind randomized controlled trial using multimodal assessments. Front Neurol. 2019;10:248.
LeWitt PA. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics: levodopa pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64–72.
Krimchansky BZ, Keren O, Sazbon L, Groswasser Z. Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. Brain Inj. 2004;18(11):1099–105.
Ugoya SO, Akinyemi RO. The place of l-Dopa/carbidopa in persistent vegetative state. Clin Neuropharmacol. 2010;33(6):279–84.
Matsuda W, Komatsu Y, Yanaka K, Matsumura A. Levodopa treatment for patients in persistent vegetative or minimally conscious states. Neuropsychological Rehabilitation. 2005;15(3–4):414–27.
Patrick PD, Buck ML, Conaway MR, Blackman JA. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj. 2003;17(6):497–506.
Bancalari E, Rabinstein A, Machiavello F, Desmaison A. Accelerated emergence from a nontraumatic minimally conscious state with levodopa/carbidopa. Neurol Clin Pract. 2018;8(6):541–2.
Roy D, Song J, Awad N, Zamudio P. Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19. BMJ Case Rep. 2021;14(3):e239781.
Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75(7):711–21.
Moein H, Khalili HA, Keramatian K. Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin Neurol Neurosurg. 2006;108(6):539–42.
Whyte J, Hart T, Schuster K, Fleming M, Polansky M, Coslett HB. Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. Am J Phys Med Rehabil. 1997;76(6):440–50.
Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004;83(6):401–20.
Martin RT, Whyte J. The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness: a meta-analysis of n-of-1 studies. Am J Phys Med Rehabil. 2007;86(8):613–20.
Reynolds JC, Rittenberger JC, Callaway CW. Methylphenidate and amantadine to stimulate reawakening in comatose patients resuscitated from cardiac arrest. Resuscitation. 2013;84(6):818–24.
Kim YW, Shin JC, An Y-s. Effects of methylphenidate on cerebral glucose metabolism in patients with impaired consciousness after acquired brain injury. Clin Neuropharmacol. 2009;32(6):335–9.
Edlow BL, Barra ME, Zhou DW, Foulkes AS, Snider SB, Threlkeld ZD, et al. Personalized connectome mapping to guide targeted therapy and promote recovery of consciousness in the intensive care unit. Neurocrit Care. 2020;33(2):364–75.
Kaelin DL, Cifu DX, Matthies B. Methylphenidate effect on attention deficit in the acutely brain-injured adult. Arch Phys Med Rehabil. 1996;77(1):6–9.
Plenger PM, Dixon CE, Castillo RM, Frankowski RF, Yablon SA, Levin HS. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil. 1996;77(6):536–40.
Naz F, Malik A, Riaz M, Mahmood Q, Mehmood MH, Rasool G, et al. Bromocriptine therapy: review of mechanism of action, safety and tolerability. Clin Exp Pharma Physiol. 2022;49(8):903–22.
Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol. 2009;41(4):197.
Munakomi S, Bhattarai B, Mohan Kumar B. Role of bromocriptine in multi-spectral manifestations of traumatic brain injury. Chin J Traumatol. 2017;20(2):84–6.
Passler MA, Riggs RV. Positive outcomes in traumatic brain injury–vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil. 2001;82(3):311–5.
Giacino JT, Kalmar K. The vegetative and minimally conscious states: a comparison of clinical features and functional outcome. J Head Trauma Rehabil. 1997;12(4):36. https://journals.lww.com/headtraumarehab/Fulltext/1997/08000/The_Vegetative_and_Minimally_Conscious_States__A.5.aspx.
Otero Villaverde S, Martin Mourelle R, Crespo Lopez C, Cabrera Sarmiento JJ, Ruiz Castillo A, Canosa Hermida E. Bromocriptine in disorders of consciousness due to traumatic brain injury. Rehabilitación. 2019;53(3):155–61.
Whyte J, Vaccaro M, Grieb-Neff P, Hart T, Polansky M, Coslett HB. The effects of bromocriptine on attention deficits after traumatic brain injury: a placebo-controlled pilot study. Am J Phys Med Rehabil. 2008;87(2):85–99.
Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat. 2007;3(3):349–64.
Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20(22):8620–8.
Schwartz J. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.
Dhamapurkar SK, Wilson BA, Rose A, Watson P, Shiel A. Does Modafinil improve the level of consciousness for people with a prolonged disorder of consciousness? A retrospective pilot study. Disabil Rehabil. 2017;39(26):2633–9.
Mo Y, Thomas MC, Miano TA, Stemp LI, Bonacum JT, Hutchins K, et al. Effect of Modafinil on cognitive function in intensive care unit patients: a retrospective cohort study. J Clin Pharmacol. 2018;58(2):152–7.
Cross DB, Tiu J, Medicherla C, Ishida K, Lord A, Czeisler B, et al. Modafinil in Recovery after Stroke (MIRAS): a retrospective study. J Stroke Cerebrovasc Dis. 2020;29(4):104645.
Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj. 2005;19(9):725–7.
Formica F, Pozzi M, Avantaggiato P, Molteni E, Arrigoni F, Giordano F, et al. Disordered consciousness or disordered wakefulness? The importance of prolonged polysomnography for the diagnosis, drug therapy, and rehabilitation of an unresponsive patient with brain injury. J Clin Sleep Med. 2017;13(12):1477–81.
Tábi T, Vécsei L, Youdim MB, Riederer P, Szöko É. Selegiline: a molecule with innovative potential. J Neural Transm. 2020;127(5):831–42.
Masotta O, Trojano L, Loreto V, Moretta P, Estraneo A. Selegiline in patients with disorder of consciousness: an open pilot study. Can J Neurol Sci. 2018;45(6):688–91.
Clauss RP, Güldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR. Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000;90(1):68–72.
Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation. 2006;21(1):23–8.
Whyte J, Myers R. Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil. 2009;88(5):410–8.
Calabrò RS, Aricò I, De Salvo S, Conti-Nibali V, Bramanti P. Transient awakening from vegetative state: is high-dose zolpidem more effective? Psychiatry Clin Neurosci. 2015;69(2):122–3.
Shames JL, Ring H. Transient reversal of anoxic brain injury-related minimally conscious state after zolpidem administration: a case report. Arch Phys Med Rehabil. 2008;89(2):386–8.
Brefel-Courbon C, Payoux P, Ory F, Sommet A, Slaoui T, Raboyeau G, et al. Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy. Ann Neurol. 2007;62(1):102–5.
Cohen SI, Duong TT. Increased arousal in a patient with anoxic brain injury after administration of zolpidem. Am J Phys Med Rehabil. 2008;87(3):229–31.
Appu M, Noetzel M. Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-d-aspartate receptor encephalitis in a teenager: a case report. Pediatr Neurol. 2014;50(3):262–4.
Lo YL, Tan EK, Ratnagopal P, Chan LL, Tan TE. Zolpidem and its effects on hypoxic encephalopathy. Ann Neurol. 2008;64(4):477–8.
Singh R, McDonald C, Dawson K, Lewis S, Pringle AM, Smith S, et al. Zolpidem in a minimally conscious state. Brain Inj. 2008;22(1):103–6.
Gosseries O, Martial C. The use of psychedelics in the treatment of disorders of consciousness. ALIUS Bull. 2020; https://aliusresearch.org/bulletin04-gosseriesinterview.html.
Whyte J, Rajan R, Rosenbaum A, Katz D, Kalmar K, Seel R, et al. Zolpidem and restoration of consciousness. Am J Phys Med Rehabil. 2014;93(2):101–13.
Thonnard M, Gosseries O, Demertzi A, Lugo Z, Vanhaudenhuyse A, Bruno MA, et al. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study. Funct Neurol. 2013;28(4):259–64.
Zhang B, O’Brien K, Won W, Li S. A retrospective analysis on clinical practice-based approaches using zolpidem and lorazepam in disorders of consciousness. Brain Sci. 2021;11(6):726.
Machado C, Est’vez M, P’rez-Nellar J, Guti’rrez J, Rodríguez R, Carballo M, et al. Autonomic, EEG, and behavioral arousal signs in a PVS case after zolpidem intake. Can J Neurol Sci. 2011;38(2):341–4.
Machado C, Estévez M, Rodríguez R, Pérez-Nellar J, Chinchilla M, DeFina P, et al. Zolpidem arousing effect in persistent vegetative state patients: autonomic, EEG and behavioral assessment. Curr Pharm Des. 2014;20(26):4185–202.
Rodriguez-Rojas R, Machado C, Álvarez L, Carballo M, Estevez M, Perez-Nellar J, et al. Zolpidem induces paradoxical metabolic and vascular changes in a patient with PVS. Brain Inj. 2013;27(11):1320–9.
Clauss R, Nel W. Effect of zolpidem on brain injury and diaschisis as detected by 99mTc HMPAO brain SPECT in humans. Arzneimittelforschung. 2011;54(10):641–6.
Pistoia F, Sarà M, Sacco S, Franceschini M, Carolei A. Silencing the brain may be better than stimulating it. The GABA effect. Curr Pharm Des. 2014;20(26):4154–66.
Qin P, Wu X, Duncan NW, Bao W, Tang W, Zhang Z, et al. GABAA receptor deficits predict recovery in patients with disorders of consciousness: a preliminary multimodal [11C]Flumazenil PET and fMRI study: GABAA receptor predicts consciousness. Hum Brain Mapp. 2015;36(10):3867–77.
Schiff ND. Recovery of consciousness after brain injury: a mesocircuit hypothesis. Trends Neurosci. 2010;33(1):1–9.
Du B, Shan A, Zhong X, Zhang Y, Chen D, Cai K. Zolpidem arouses patients in vegetative state after brain injury: quantitative evaluation and indications. Am J Med Sci. 2014;347(3):178–82.
Hall SD, Yamawaki N, Fisher AE, Clauss RP, Woodhall GL, Stanford IM. GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke—a case report. Clin Neurophysiol. 2010;121(4):549–55.
Hao Z, Xia X, Bai Y, Wang Y, Dou W. EEG evidence reveals zolpidem-related alterations and prognostic value in disorders of consciousness. Front Neurosci. 2022;16:863016.
Gao Q, Hao J, Kang X, Yuan F, Liu Y, Chen R, et al. EEG dynamics induced by zolpidem forecast consciousness evolution in prolonged disorders of consciousness. Clin Neurophysiol. 2023;153:46–56.
Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med. 2004;350(9):949–50.
Arnts H, Van Erp WS, Boon LI, Bosman CA, Admiraal MM, Schrantee A, et al. Awakening after a sleeping pill: restoring functional brain networks after severe brain injury. Cortex. 2020;132:135–46.
Delargy M, O’Connor R, McCann A, Galligan I, Cronin H, Gray D, et al. An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC). Brain Inj. 2019;33(2):242–8.
Snyman N, Egan JR, London K, Howman-Giles R, Gill D, Gillis J, et al. Zolpidem for persistent vegetative state—a placebo-controlled trial in pediatrics. Neuropediatrics. 2010;41(05):223–7.
Pistoia F, Sacco S, Sarà M, Franceschini M, Carolei A. Intrathecal baclofen: effects on spasticity, pain, and consciousness in disorders of consciousness and locked-in syndrome. Curr Pain Headache Rep. 2015;19(1):466.
Turner MS. Early use of intrathecal baclofen in brain injury in pediatric patients. In: Katayama Y, editor. Neurosurgical re-engineering of the damaged brain and spinal cord. Vienna: Springer Vienna; 2003. p. 81–3. https://doi.org/10.1007/978-3-7091-6081-7_17.
Kawecki Z, Kwiatkowski S, Grzegorzewski P, Szlachta Jezioro I. Sudden improvement of all neurological functions after general anesthesia and two-day intrathecal infusion of baclofen in a child with primary brain-stem injury. Przegl Lek. 2007;64(Suppl 2):13–4.
Sarà M, Sacco S, Cipolla F, Onorati P, Scoppetta C, Albertini G, et al. An unexpected recovery from permanent vegetative state. Brain Inj. 2007;21(1):101–3.
Taira T. Intrathecal administration of GABA agonists in the vegetative state. In: Progress in brain research. Elsevier; 2009. p. 317–28. https://linkinghub.elsevier.com/retrieve/pii/S007961230917721X.
Sarà M, Pistoia F, Mura E, Onorati P, Govoni S. Intrathecal baclofen in patients with persistent vegetative state: 2 hypotheses. Arch Phys Med Rehabil. 2009;90(7):1245–9.
Al-Khodairy AT, Wicky G, Nicolo D, Vuadens P. Influence of intrathecal baclofen on the level of consciousness and mental functions after extremely severe traumatic brain injury: brief report. Brain Inj. 2015;29(4):527–32.
Margetis K, Korfias SI, Gatzonis S, Boutos N, Stranjalis G, Boviatsis E, et al. Intrathecal baclofen associated with improvement of consciousness disorders in spasticity patients. Neuromodulation. 2014;17(7):699–704.
Hoarau X, Richer E, Dehail P, Cuny E. Comparison of long-term outcomes of patients with severe traumatic or hypoxic brain injuries treated with intrathecal baclofen therapy for dysautonomia. Brain Inj. 2012;26(12):1451–63.
Hoarau X, Richer E, Dehail P, Cuny E. A 10-year follow-up study of patients with severe traumatic brain injury and dysautonomia treated with intrathecal baclofen therapy. Brain Inj. 2012;26(7–8):927–40.
Dvorak EM, McGuire JR, Nelson MES. Incidence and identification of intrathecal baclofen catheter malfunction. PM&R. 2010;2(8):751–6.
Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735–41.
Clauss RP. Neurotransmitters in disorders of consciousness and brain damage. Med Hypotheses. 2011;77(2):209–13.
Andrade C. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Mens Sana Monogr. 2010;8(1):146.
Oliveira L, Fregni F. Pharmacological and electrical stimulation in chronic disorders of consciousness: new insights and future directions. Brain Inj. 2011;25(4):315–27.
Schiff ND. Central thalamic deep-brain stimulation in the severely injured brain: rationale and proposed mechanisms of action. Ann N Y Acad Sci. 2009;1157(1):101–16.
Schiff ND. Recovery of consciousness after severe brain injury: the role of arousal regulation mechanisms and some speculation on the heart-brain interface. CCJM. 2010;77(7 Suppl 3):S27–33.
Helbok R, Rass V, Beghi E, Bodien YG, Citerio G, Giacino JT, et al. The curing coma campaign international survey on coma epidemiology, evaluation, and therapy (COME TOGETHER). Neurocrit Care. 2022;37(1):47–59.
Claassen J, Akbari Y, Alexander S, Bader MK, Bell K, Bleck TP, et al. Proceedings of the First Curing Coma Campaign NIH Symposium: challenging the future of research for coma and disorders of consciousness. Neurocrit Care. 2021;35(S1):4–23.
Fridman EA, Schiff ND. Organizing a rational approach to treatments of disorders of consciousness using the anterior forebrain mesocircuit model. J Clin Neurophysiol. 2022;39(1):40–8.
Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41–7.
Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson Disease. Arch Neurol. 2010;67(1):58–63. https://doi.org/10.1001/archneurol.2009.294.
Herrold AA, Pape TLB, Guernon A, Mallinson T, Collins E, Jordan N. Prescribing multiple neurostimulants during rehabilitation for severe brain injury. Sci World J. 2014;2014:1–7.
Hammond FM, Barrett RS, Shea T, Seel RT, McAlister TW, Kaelin D, et al. Psychotropic medication use during inpatient rehabilitation for traumatic brain injury. Arch Phys Med Rehabil. 2015;96(8):S256–S273.e14.
Larson EB. N-of-1 trials: a new future? J Gen Intern Med. 2010;25(9):891–2.
Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Pers Med. 2011;8(2):161–73.
Backman CL, Harris SR, Chisholm JAM, Monette AD. Single-subject research in rehabilitation: a review of studies using AB, withdrawal, multiple baseline, and alternating treatments designs. Arch Phys Med Rehabil. 1997;78(10):1145–53.
Ottenbacher KJ. Evaluating clinical change: strategies for occupational and physical therapists. Baltimore, MD: Williams & Wilkins; 1986. p. 243.
Whyte J. Design of brain injury rehabilitation treatment research. In: Handbook of clinical neurology. Elsevier; 2015. p. 779–94. https://linkinghub.elsevier.com/retrieve/pii/B9780444635211000480.
Sarasso S, Casali AG, Casarotto S, Rosanova M, Sinigaglia C, Massimini M. Consciousness and complexity: a consilience of evidence. Neurosci Conscious. 2021;2021:niab023.
Tononi G. Consciousness and complexity. Science. 1998;282(5395):1846–51.
Casali AG, Gosseries O, Rosanova M, Boly M, Sarasso S, Casali KR, et al. A theoretically based index of consciousness independent of sensory processing and behavior. Sci Transl Med. 2013;5:198. https://doi.org/10.1126/scitranslmed.3006294.
Casarotto S, Comanducci A, Rosanova M, Sarasso S, Fecchio M, Napolitani M, et al. Stratification of unresponsive patients by an independently validated index of brain complexity. Ann Neurol. 2016;80(5):718–29.
Comolatti R, Pigorini A, Casarotto S, Fecchio M, Faria G, Sarasso S, et al. A fast and general method to empirically estimate the complexity of brain responses to transcranial and intracranial stimulations. Brain Stimul. 2019;12(5):1280–9.
Scott G, Carhart-Harris RL. Psychedelics as a treatment for disorders of consciousness. Neurosci Conscious. 2019; https://doi.org/10.1093/nc/niz003/5475888.
Ort A, Smallridge JW, Sarasso S, Casarotto S, Von Rotz R, Casanova A, et al. TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology. iScience. 2023;26(5):106589.
Farnes N, Juel BE, Nilsen AS, Romundstad LG, Storm JF. Increased signal diversity/complexity of spontaneous EEG, but not evoked EEG responses, in Ketamine-induced psychedelic state in humans. PLoS One. 2020;15(11):e0242056.
Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep. 2017;7(1):46421.
Peterson A, Tagliazucchi E, Weijer C. The ethics of psychedelic research in disorders of consciousness. Neurosci Consciousess. 2019;2019(1):niz013.
Rankaduwa S, Owen AM. Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives. Neurosci Conscious. 2023;2023(1):niad001.
Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021;35(2):109–23.
Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: a paradigm shift for depression research and treatment. Neuron. 2019;101(5):774–8.
Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328–34.
Luppi AI, Cabral J, Cofre R, Mediano PAM, Rosas FE, Qureshi AY, et al. Computational modelling in disorders of consciousness: closing the gap towards personalised models for restoring consciousness. NeuroImage. 2023;275:120162.
Deco G, Cabral J, Saenger VM, Boly M, Tagliazucchi E, Laufs H, et al. Perturbation of whole-brain dynamics in silico reveals mechanistic differences between brain states. NeuroImage. 2018;169:46–56.
Cofré R, Herzog R, Mediano PAM, Piccinini J, Rosas FE, Sanz Perl Y, et al. Whole-brain models to explore altered states of consciousness from the bottom up. Brain Sci. 2020;10(9):626.
Vohryzek J, Cabral J, Vuust P, Deco G, Kringelbach ML. Understanding brain states across spacetime informed by whole-brain modelling. Phil Trans R Soc A. 2022;380(2227):20210247.
Alnagger N, Cardone P, Martial C, Laureys S, Annen J, Gosseries O. The current and future contribution of neuroimaging to the understanding of disorders of consciousness. Presse Med. 2023;52(2):104163.
Luppi AI, Mediano PAM, Rosas FE, Allanson J, Pickard JD, Williams GB, et al. Whole-brain modelling identifies distinct but convergent paths to unconsciousness in anaesthesia and disorders of consciousness. Commun Biol. 2022;5(1):384.
Herzog R, Mediano PAM, Rosas FE, Lodder P, Carhart-Harris R, Perl YS, et al. A whole-brain model of the neural entropy increase elicited by psychedelic drugs. Sci Rep. 2023;13(1):6244.
López-González A, Panda R, Ponce-Alvarez A, Zamora-López G, Escrichs A, Martial C, et al. Loss of consciousness reduces the stability of brain hubs and the heterogeneity of brain dynamics. Commun Biol. 2021;4(1):1037.
Perl YS, Bocaccio H, Pérez-Ipiña I, Zamberlán F, Piccinini J, Laufs H, et al. Generative embeddings of brain collective dynamics using variational autoencoders. Phys Rev Lett. 2020;125(23):238101.
Perl YS, Pallavicini C, Piccinini J, Demertzi A, Bonhomme V, Martial C, et al. Low-dimensional organization of global brain states of reduced consciousness. Cell Rep. 2023;42(5):112491.
Erol T, Mendi AF, Dogan D. The digital twin revolution in healthcare. In: 2020 4th International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT) [Internet]. Istanbul, Turkey: IEEE; 2020. p. 1–7. https://ieeexplore.ieee.org/document/9255249/.